REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis — StellaPhase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations(16 sites)
Austria
Medizinische Universität Graz, Graz Medical University of Vienna, Vienna Germany
Ludwig-Maximilians-University Munich, München Spain
Hospital de Vinalopó, Elche, Alicante Hospital Universitari Sant Joan de Reus, Reus, Tarragona Hospital General Universitario Dr. Balmis, Alicante Hospital de Cruces, Barakaldo UOMI Cancer Center, Barcelona Hospital Universitari Vall d'Hebron, Barcelona Institut Català d' Oncologia Girona (ICO), Girona Hospital Universitario de León, León Hospital Lucus Agusti, Lugo Hospital Beata María Ana, Madrid Hospital Universitario Vithas Madrid La Milagrosa, Madrid Complejo Hospitalario Universitario de Santiago (CHUS), Santiago de Compostela Hospital Clínico Universitario de Valencia, Valencia Last updated February 2026